Son, SooHuang, RenjieSquire, ChristopherLeung, Ka Ho Ivanhoe2018-12-062019-01Drug discovery today 24(1):206-216 Jan 20191359-6446https://hdl.handle.net/2292/44893The spread of a novel mobile colistin resistance gene (mcr1) has jeopardised the use of polymyxins, last-resort antibiotics that are used increasingly to treat infections caused by multidrug-resistant (MDR) Gram-negative pathogens. In early 2017, the WHO reported the global spread of mcr1 within a few years after its initial discovery in China. The protein encoded by mcr1 is a putative 60-kDa phosphoethanolamine (pEtN) transferase, MCR-1, and has been studied extensively since its discovery. Herein, we present a comprehensive review of MCR-1 covering its structure, function, and mechanism, to call for the rational drug design of molecular inhibitors of MCR-1 to use in colistin-based combination therapies.Print-ElectronicItems in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher.https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htmhttps://creativecommons.org/licenses/by-nc-nd/4.0BacteriaPolymyxinsTransferasesEscherichia coli ProteinsAnti-Bacterial AgentsMicrobial Sensitivity TestsDrug Resistance, BacterialProtein ConformationJournal Article10.1016/j.drudis.2018.07.004Copyright: Elsevierhttp://purl.org/eprint/accessRights/OpenAccess1878-5832